Trial Profile
Phase 1 Open-Label Dose-Escalating Study Evaluating the Safety and Preliminary Efficacy of TXA127 in Patients With Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 Sep 2016
Price :
$35
*
At a glance
- Drugs Angiotensin-1-7 (Primary)
- Indications Thrombocytopenia
- Focus Adverse reactions
- Sponsors US Biotest Inc
- 01 Dec 2014 New trial record